The Australian medical community is buzzing with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. This https://minibookmarks.com/story21718568/retatrutide-australia-australia-a-emerging-solution-for-obesity-treatment